The Business Behind...
Health Care: Drugs
Medgenics Inc (MDGN: AMEX)
$4.15 -0.03 | -0.72%
05/21/13 - 03:34 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | |||
| Sales | 0.00 | 0.00 | ||
| Cost of Sales | 0.00 | 0.00 | ||
| Gross Operating Profit | 0.00 | 0.00 | ||
| Selling, General, and Administrative Expenses | 7.20M | 4.92M | ||
| Research & Development | 5.43M | 5.05M | ||
| Operating Income before D & A (EBITDA) | -12.63M | -9.98M | ||
| Depreciation & Amortization | 145.00K | 98.00K | ||
| Interest Income | 5.00K | 2.10M | ||
| Other Income - Net | 0.00 | 0.00 | ||
| Special Income / Charges | 0.00 | 0.00 | ||
| Total Income Before Interest Expenses (EBIT) | -12.77M | -7.98M | ||
| Interest Expense | 2.43M | 214.00K | ||
| Pre-Tax Income | -15.20M | -8.19M | ||
| Income Taxes | 19.00K | 3.00K | ||
| Minority Interest | 0.00 | 0.00 | ||
| Net Income From Continuing Operations | -15.07M | 0.00 | ||
| Net Income From Discontinued Operations | 0.00 | 0.00 | ||
| Net Income From Total Operations | -15.07M | 0.00 | ||
| Extraordinary Income/Losses | 0.00 | 0.00 | ||
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | ||
| Income From Tax Loss Carryforward | 0.00 | 0.00 | ||
| Other Gains / Losses | 0.00 | 0.00 | ||
| Total Net Income | -15.07M | -8.10M | ||
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-15.07M | 0.00 | ||
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -15.07M | 0.00 | ||
| Basic EPS from Continuing Ops. | -1.37 | -0.96 | ||
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | ||
| Basic EPS from Total Operations | -1.37 | -0.96 | ||
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | ||
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | ||
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | ||
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | ||
| Basic EPS, Total | -1.37 | -0.96 | ||
| Basic Normalized Net Income/Share | -1.37 | n.a. | ||
| EPS fr Continuing Ops. | -1.37 | -0.96 | ||
| EPS fr Discontinued Ops | 0.00 | 0.00 | ||
| EPS fr Total Ops. | -1.37 | -0.96 | ||
| EPS fr Extraord. Inc. | 0.00 | 0.00 | ||
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | ||
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | ||
| EPS fr Other Gains (L) | 0.00 | 0.00 | ||
| EPS, Total | -1.37 | -0.96 | ||
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.37 | n.a. | ||
| Dividends Paid per Share | 0.00 | 0.00 | ||
Portfolios with MDGN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- UserStocks
Latest MDGN Headlines from TheStreet
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 5 Stocks Under $10 Set to Soar 10.25.12 | 12:10 pm
Press Releases for MDGN
- Medgenics Announces Exercise By Underwriters Of Over-Allotment Option - Business Wire 03.26.13 | 09:03 am
- Medgenics To Present At The 25th Annual Roth Conference - Business Wire 03.15.13 | 09:03 am
- Medgenics Reports 2012 Financial Results - Business Wire 03.14.13 | 09:03 am
- Medgenics Appoints Former Chairman And CEO Of UBS Financial Services Joseph J. Grano, Jr. To Board Of Directors - Business Wire 03.12.13 | 09:03 am
- Medgenics Announces Closing Of Public Offering Of Common Stock And Warrants - Business Wire 02.14.13 | 04:02 am
- Medgenics Prices Public Offering Of Common Stock And Warrants - Business Wire 02.08.13 | 02:02 am
- Medgenics Launches First Clinical Trial In Hepatitis To Use INFRADURE Tissue Treatment - Business Wire 01.30.13 | 07:01 am
- Medgenics, Inc. (the “Company”) Issue Of Options And Restricted Shares To Directors And Officers - Business Wire 01.04.13 | 12:01 pm
- Medgenics Key Patent Claims Allowed In Japan Protecting Core Technology To Be Used In Hepatitis Treatment - Business Wire 12.06.12 | 09:12 am
- Renowned Experts Affirm Potential Of Medgenics’ INFRADURE Technology For The Treatment Of Hepatitis B And D - Business Wire 11.28.12 | 09:11 am
Partner Headlines for MDGN
- Medgenics Wins Patent for Core Technology Used in Sustained Delivery of Erythropoietin - Benzinga 11.21.12 | 09:11 am
- Medgenics Announces Approval of Two Phase I/II Clinical Trials By Israel Regulator - Benzinga 08.29.12 | 01:08 pm
- Medgenics' Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel - Benzinga 08.29.12 | 01:08 pm
- Ultimate Market Recap: Samsung on an Earnings Streak, More iPad Mini Evidence - Wall St. Cheat Sheet 07.06.12 | 09:07 am
- Boston Beer Co. INTRODUCES New Summer Lager and 4 End-of-Week Hot Stocks - Wall St. Cheat Sheet 07.06.12 | 02:07 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Medgenics MOVES Forward with Hepatitis D Drug and 2 More Stocks Hitting 52-Week Highs - Wall St. Cheat Sheet 06.21.12 | 10:06 am
- The Bio Pharma Momentum Movers List For Thursday, June 21 - Seeking Alpha 06.21.12 | 09:06 am
- Medgenics Raises $9.5 Million in Private Placement - Benzinga 06.19.12 | 09:06 am
- Medgenics Raises $9.5 Million in Private Placement - Benzinga 06.19.12 | 09:06 am
